William Blair Estimates Incyte's Q1 Earnings (NASDAQ:INCY)

Incyte Co. (NASDAQ:INCY - Free Report) - Stock analysts at William Blair reduced their Q1 2025 EPS estimates for Incyte in a research report issued on Monday, April 14th. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will post earnings of $0.76 per share for the quarter, down from their prior estimate of $0.77. William Blair currently has a "Market Perform" rating on the stock. The consensus estimate for Incyte's current full-year earnings is $4.86 per share.

Several other equities analysts have also issued reports on the company. JMP Securities reaffirmed a "market perform" rating on shares of Incyte in a report on Tuesday, February 11th. Guggenheim cut Incyte from a "buy" rating to a "neutral" rating and set a $92.00 price objective for the company. in a research note on Tuesday, March 18th. Citigroup cut their target price on shares of Incyte from $97.00 to $88.00 and set a "buy" rating on the stock in a report on Tuesday, February 11th. Morgan Stanley lowered their price objective on shares of Incyte from $69.00 to $65.00 and set an "equal weight" rating on the stock in a research report on Monday, March 24th. Finally, Stifel Nicolaus upped their price objective on Incyte from $75.00 to $77.00 and gave the stock a "hold" rating in a report on Monday, February 10th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and six have issued a buy rating to the company's stock. Based on data from MarketBeat, Incyte currently has an average rating of "Hold" and an average target price of $74.88.

Incyte Stock Up 0.8 %

Shares of Incyte stock traded up $0.48 during trading hours on Wednesday, hitting $58.21. The company had a trading volume of 1,172,156 shares, compared to its average volume of 2,377,197. The company's 50-day moving average is $64.84 and its two-hundred day moving average is $69.31. Incyte has a twelve month low of $50.35 and a twelve month high of $83.95. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.97 and a quick ratio of 1.94. The company has a market cap of $11.27 billion, a P/E ratio of 215.60, a price-to-earnings-growth ratio of 0.41 and a beta of 0.89.

Incyte (NASDAQ:INCY - Get Free Report) last announced its quarterly earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.48). Incyte had a net margin of 0.77% and a return on equity of 0.05%.

Insiders Place Their Bets

In related news, EVP Sheila A. Denton sold 14,069 shares of the business's stock in a transaction dated Wednesday, February 26th. The shares were sold at an average price of $74.07, for a total transaction of $1,042,090.83. Following the completion of the sale, the executive vice president now owns 25,848 shares of the company's stock, valued at $1,914,561.36. This represents a 35.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Steven H. Stein sold 12,352 shares of the firm's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $72.69, for a total transaction of $897,866.88. Following the completion of the transaction, the executive vice president now directly owns 66,967 shares in the company, valued at $4,867,831.23. This represents a 15.57 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 46,827 shares of company stock valued at $3,322,618 in the last quarter. Insiders own 17.60% of the company's stock.

Institutional Trading of Incyte

A number of large investors have recently modified their holdings of the company. Geode Capital Management LLC grew its holdings in Incyte by 2.6% in the 4th quarter. Geode Capital Management LLC now owns 4,040,086 shares of the biopharmaceutical company's stock worth $278,346,000 after buying an additional 103,910 shares in the last quarter. AQR Capital Management LLC lifted its holdings in Incyte by 29.7% in the fourth quarter. AQR Capital Management LLC now owns 3,502,813 shares of the biopharmaceutical company's stock worth $241,519,000 after purchasing an additional 801,090 shares during the period. LSV Asset Management increased its stake in Incyte by 18.6% during the 4th quarter. LSV Asset Management now owns 3,467,490 shares of the biopharmaceutical company's stock valued at $239,500,000 after buying an additional 544,080 shares during the period. Bellevue Group AG raised its position in shares of Incyte by 0.3% during the 4th quarter. Bellevue Group AG now owns 2,157,478 shares of the biopharmaceutical company's stock worth $149,017,000 after buying an additional 6,927 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Incyte in the fourth quarter valued at approximately $121,890,000. Institutional investors and hedge funds own 96.97% of the company's stock.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.